Details for New Drug Application (NDA): 208083
✉ Email this page to a colleague
The generic ingredient in CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
Summary for 208083
Tradename: | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE |
Applicant: | Baxter Hlthcare Corp |
Ingredient: | clindamycin phosphate |
Patents: | 0 |
Pharmacology for NDA: 208083
Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |
Suppliers and Packaging for NDA: 208083
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083 | NDA | Baxter Healthcare Company | 0338-9545 | 0338-9545-24 | 24 BAG in 1 CARTON (0338-9545-24) / 50 mL in 1 BAG (0338-9545-50) |
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083 | NDA | Baxter Healthcare Company | 0338-9549 | 0338-9549-24 | 24 BAG in 1 CARTON (0338-9549-24) / 50 mL in 1 BAG (0338-9549-50) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 300MG BASE/50ML (EQ 6MG BASE/ML) | ||||
Approval Date: | Apr 20, 2017 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 600MG BASE/50ML (EQ 12MG BASE/ML) | ||||
Approval Date: | Apr 20, 2017 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 900MG BASE/50ML (EQ 18MG BASE/ML) | ||||
Approval Date: | Apr 20, 2017 | TE: | RLD: | Yes |
Complete Access Available with Subscription